Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1938]

PET-Directed therapy for early-stage diffuse large B-cell lymphoma

Prof Daniel Persky - University of Arizona Cancer Center, Tucson, USA

PET-Directed therapy for early-stage diffuse large B-cell lymphoma ( Prof Daniel Persky - University of Arizona Cancer Center, Tucson, USA )

Lenalidomide maintenance for transplant eligible and transplant ineligible...

Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK

Lenalidomide maintenance for transplant eligible and transplant ineligible newly diagnosed myeloma patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )

Dasatinib vs imatinib in the treatment of paediatric ALL

Dr Shuhong Shen - National Children's Medical Center, Shanghai, China

Dasatinib vs imatinib in the treatment of paediatric ALL ( Dr Shuhong Shen - National Children's Medical Center, Shanghai, China )

Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells...

Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern...

Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans ( Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switzerland )

Prognostic impact of chromosomal abnormalities and copy number alterations in B...

Prof Anthony Moorman - Newcastle University, Newcastle, UK

Prognostic impact of chromosomal abnormalities and copy number alterations in B-cell precursor ALL treated on UKALL14 ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )

Long-term outcomes of subjects with EBV driven PTLD following solid organ or...

Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA

Long-term outcomes of subjects with EBV driven PTLD following solid organ or allogeneic HCT treated with tabelecleucel ( Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA )

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT...

Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo ( Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA )

Outcomes in patients with therapy-Related AML who achieved remission with CPX...

Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa...

Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis ( Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML...

Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )

Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with...

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )

Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from...

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )

LYRA: Maintenance therapy with daratumumab improves depth of response and...

Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA

LYRA: Maintenance therapy with daratumumab improves depth of response and achieves durable remissions in MM patients ( Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA )

More from ecancer